company background image
ARUX.F logo

Acrux OTCPK:ARUX.F Stock Report

Last Price

US$0.031

Market Cap

US$9.3m

7D

0%

1Y

n/a

Updated

23 Mar, 2024

Data

Company Financials +

ARUX.F Stock Overview

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally.

ARUX.F fundamental analysis
Snowflake Score
Valuation4/6
Future Growth6/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Acrux Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Acrux
Historical stock prices
Current Share PriceAU$0.031
52 Week HighAU$0.043
52 Week LowAU$0.031
Beta1.24
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Change-73.39%
5 Year Change-74.50%
Change since IPO-96.88%

Recent News & Updates

Recent updates

Shareholder Returns

ARUX.FUS PharmaceuticalsUS Market
7D0%-0.06%2.1%
1Yn/a23.6%30.4%

Return vs Industry: Insufficient data to determine how ARUX.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ARUX.F performed against the US Market.

Price Volatility

Is ARUX.F's price volatile compared to industry and market?
ARUX.F volatility
ARUX.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.3%
Market Average Movement6.0%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.0%

Stable Share Price: ARUX.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine ARUX.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1998n/aMichael Kotsanishttps://www.acrux.com.au

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of males. It also provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; and lidocaine and prilocaine cream, a generic version of EMLA cream, which is indicated as a topical anaesthetic for use on normal intact skin for local analgesia, and genital mucous membranes for superficial minor surgery and as a pre-treatment for infiltration anaesthesia.

Acrux Limited Fundamentals Summary

How do Acrux's earnings and revenue compare to its market cap?
ARUX.F fundamental statistics
Market capUS$9.28m
Earnings (TTM)-US$461.74k
Revenue (TTM)US$7.44m

1.2x

P/S Ratio

-20.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ARUX.F income statement (TTM)
RevenueAU$11.42m
Cost of RevenueAU$7.03m
Gross ProfitAU$4.39m
Other ExpensesAU$5.10m
Earnings-AU$709.00k

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0024
Gross Margin38.46%
Net Profit Margin-6.21%
Debt/Equity Ratio0%

How did ARUX.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.